Overview

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

Status:
Terminated

Trial end date:
2019-10-25

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to characterize the safety and tolerability of andecaliximab as monotherapy and in combination with anti-cancer agents in Japanese participants with inoperable advanced or recurrent gastric or recurrent gastroesophageal junction (GEJ) adenocarcinoma.

Phase:

Phase 1

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Cisplatin
Nivolumab
Oxaliplatin